US20040132967A1 - Respiratory distress syndrome therapy with peptide analogs of human SP-B - Google Patents
Respiratory distress syndrome therapy with peptide analogs of human SP-B Download PDFInfo
- Publication number
- US20040132967A1 US20040132967A1 US10/730,964 US73096403A US2004132967A1 US 20040132967 A1 US20040132967 A1 US 20040132967A1 US 73096403 A US73096403 A US 73096403A US 2004132967 A1 US2004132967 A1 US 2004132967A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- dimer
- lung
- surfactant
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 title claims abstract description 83
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims abstract description 19
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 74
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 8
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims abstract description 67
- 239000000539 dimer Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims description 45
- 210000004072 lung Anatomy 0.000 claims description 38
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 claims description 20
- 239000003580 lung surfactant Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 229940066294 lung surfactant Drugs 0.000 claims description 18
- 150000003904 phospholipids Chemical class 0.000 claims description 18
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000000710 homodimer Substances 0.000 claims description 15
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 12
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims description 11
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 208000023504 respiratory system disease Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 102000057010 human SFTPB Human genes 0.000 abstract description 4
- 210000004898 n-terminal fragment Anatomy 0.000 abstract description 4
- 230000005714 functional activity Effects 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 239000000178 monomer Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 19
- 241000700159 Rattus Species 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 229940063649 survanta Drugs 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 9
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000002983 circular dichroism Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 6
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000006213 oxygenation reaction Methods 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IHRGVZXPTIQNIP-NAKRPEOUSA-N Ala-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)N IHRGVZXPTIQNIP-NAKRPEOUSA-N 0.000 description 4
- YQGZIRIYGHNSQO-ZPFDUUQYSA-N Arg-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YQGZIRIYGHNSQO-ZPFDUUQYSA-N 0.000 description 4
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- FZBGMXYQPACKNC-HJWJTTGWSA-N Phe-Pro-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FZBGMXYQPACKNC-HJWJTTGWSA-N 0.000 description 4
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 4
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 4
- YWXMGBUGMLJMIP-IHPCNDPISA-N Tyr-Cys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC3=CC=C(C=C3)O)N YWXMGBUGMLJMIP-IHPCNDPISA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003434 inspiratory effect Effects 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108010079317 prolyl-tyrosine Proteins 0.000 description 4
- 238000009256 replacement therapy Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012876 topography Methods 0.000 description 4
- 108010080629 tryptophan-leucine Proteins 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102000017852 Saposin Human genes 0.000 description 3
- 108050007079 Saposin Proteins 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- WUHJHHGYVVJMQE-BJDJZHNGSA-N Ala-Leu-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WUHJHHGYVVJMQE-BJDJZHNGSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 2
- NFHJQETXTSDZSI-DCAQKATOSA-N Leu-Cys-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NFHJQETXTSDZSI-DCAQKATOSA-N 0.000 description 2
- HNDWYLYAYNBWMP-AJNGGQMLSA-N Leu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N HNDWYLYAYNBWMP-AJNGGQMLSA-N 0.000 description 2
- 108010010224 NK-lysin Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000596 artificial lung surfactant Substances 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940092456 curosurf Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940026289 infasurf Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- GOAXVYWKZBXRQP-UHFFFAOYSA-N 2-amino-1,1,2-trifluoroethanol Chemical compound NC(F)C(O)(F)F GOAXVYWKZBXRQP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000612662 Bos taurus Pulmonary surfactant-associated protein C Proteins 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MBPKYKSYUAPLMY-DCAQKATOSA-N Cys-Arg-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MBPKYKSYUAPLMY-DCAQKATOSA-N 0.000 description 1
- VCPHQVQGVSKDHY-FXQIFTODSA-N Cys-Ser-Met Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O VCPHQVQGVSKDHY-FXQIFTODSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- KHHDJQRWIFHXHS-NRPADANISA-N Gln-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N KHHDJQRWIFHXHS-NRPADANISA-N 0.000 description 1
- LUJVWKKYHSLULQ-ZKWXMUAHSA-N Gly-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN LUJVWKKYHSLULQ-ZKWXMUAHSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- -1 Saposins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 101710200413 Small hydrophobic protein Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- FTKXYXACXYOHND-XUXIUFHCSA-N Val-Ile-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O FTKXYXACXYOHND-XUXIUFHCSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 239000007862 dimeric product Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000013035 low temperature curing Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010091085 protozoan amoebapore proteins Proteins 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
Definitions
- the present invention relates generally to a therapeutic pharmaceutical composition for the treatment of respiratory disease, including particularly Respiratory Distress Syndrome (RDS) comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.
- RDS Respiratory Distress Syndrome
- SP-B Surfactant Protein B
- the human lung is composed of a large number of small air sacs, called alveoli, in which gases are exchanged between the blood and the air spaces of the lungs. In healthy individuals, this exchange is mediated by the presence of a protein-containing surfactant complex. Lung surfactant complex is composed primarily of lipid and contains a minor component of various proteins. An absence of adequate levels of this complex results in malfunction of the lung. This syndrome is called Respiratory Distress Syndrome (RDS). Adult RDS is correlated with an absence or dysfunction of the lung surfactant at the alveoli membrane where the gas exchange occurs.
- RDS Respiratory Distress Syndrome
- the adult disease results from lung insults such as diffuse infections, aspiration of the gastric contents or water, inhalation of irritants and toxins and pulmonary edema arising from such sources as narcotic overdose.
- the syndrome is also common in premature infants and is associated with immaturity and low birth weight. Of those pre-term infants afflicted, approximately 10% die. Infantile respiratory distress syndrome is the leading cause of death in the first twenty-eight days of life.
- the composition of native lung surfactant is lipid (approximately 90%-97%) and various proteins (approximately 10%).
- the primary lipid type is phospholipid and constitutes 97% of the total lipid. 80% of this phospholipid is phosphatidylcholine (PC) and 10% is phosphatidyglycerol (PG). 70-80% of the phospholipid acyl chains are saturated.
- the major lipid is dipalmitoylphosphatidylcholine (DPPC).
- DPPC dipalmitoylphosphatidylcholine
- surfactant-associated proteins are known to exist: two are glycoproteins, SP-A and SP-D, and two are small hydrophobic proteins, SP-C and SP-B.
- Human lung surfactant contains a hydrophobic SP-B peptide, which is usually present as a dimer.
- the SP-B functions by reducing the surface tension of alveoli to prevent collapse of the lung air sacs, thereby preventing respiratory distress.
- surfactant replacement therapies focused on using the lipid components alone. It was later found that the therapy's performance was greatly improved by the use of the apoprotein in similar proportion to native human surfactant.
- Infasurf is a natural surfactant extract from calf lung lavage. Infasurf is also comprised of phospholipids and SP-B & SP-C. Another commercially available natural lung surfactant is Survanta®, manufactured by Abbott Labs, a chemically modified natural bovine lung extract.
- the present invention includes a pharmaceutical composition of synthetic peptides used to treat respiratory disorders.
- the composition may also be added to existing treatments to enhance the biological activity of existing pulmonary surfactant dispersions for the treatment of RDS.
- the invention preferably provides a composition of novel synthetic peptide analogs of SP-B that mimic the active site of native Surfactant Protein B (SP-B).
- SP-B Surfactant Protein B
- the composition of the invention may be used to supplement naturally derived lung surfactants or to formulate synthetic lung surfactant lipid-peptide dispersions. See Walther, F. J., Hernandez-Juviel, J., Bruni, R., Waring, A.
- the synthetic peptide of the present invention mimics the active site of the SP-B protein and creates a synthetic analog of these amino acids to augment the properties of the native proteins.
- the SP-B analogs of the present invention are based on the known primary sequence of native mammalian SP-B and in a preferred embodiment, human SP-B.
- a covalently linked dimer of the constituent N-terminus SP-B domain (amino acids 1-25), herein referred to as the SP-B1-25 dimer, may replace or supplement full length proteins currently used to treat RDS.
- the SP-B1-25 dimer may replace or supplement full length proteins currently used to treat RDS.
- the human peptide is more effective than other natural SP-B derived from animal sources, the creation of a synthetic peptide that mimics human SP-B is more efficacious in the treatment of RDS than natural surfactants derived from animals.
- the dimeric SP-B1-25 exhibits advantageous physical and chemical characteristics in analyses that reflect the desired properties of surface tension at the air/liquid interface of the lung.
- the SP-B1-25 dimer can be formulated in therapeutic compositions for the treatment of respiratory disorders, and can be used in methods designed to treat respiratory disorders when clinically indicated.
- FIG. 1 is the amino acid sequence in three letter code of native human surfactant protein B (SP-B).
- FIG. 2 is the amino acid sequence in one letter code of SP-B1-25 of native human SP-B1-25 and the Cys 11 ⁇ Ala 11 variant monomer.
- FIG. 3 is the amino acid sequence in one letter code of the SP-B1-25 Cys 11 ⁇ Ala 11 variant disulfide linked homodimer of the present invention.
- FIG. 4 is a fast atom bombardment electrospray mass spectrograph of the SP-B1-25.
- FIG. 5 is a Circular Dichroism (CD) spectrum of SP-B1-25 dimer in a structure promoting solvent system of trifluoroethanolamine (TFE):phosphate buffer.
- CD Circular Dichroism
- FIG. 6 is a CD spectrum of SP-B1-25 dimer in palmitoylolsoyl phosphatidyl glycerol (POPG) liposomes with phosphate buffered saline (PBS) palmitoyl olcoyl phosphatidyl glycerol buffer.
- POPG palmitoylolsoyl phosphatidyl glycerol
- PBS phosphate buffered saline
- FIG. 7 is a measurement of oxygenation in lavaged rat lungs comparing a standard phospholipid mixture (PL)- ⁇ -, Survanta - ⁇ -, the SP-B1-25 monomer - ⁇ -, and the SP-B1-25 dimer of the present invention - ⁇ -.
- PL standard phospholipid mixture
- FIG. 8 is a measurement of lavaged rat lung volume as a function of pressure comparing a standard phospholipid mixture (PL) - ⁇ -, Survanta - ⁇ -, the SP-B1-25 monomer - ⁇ -, and the SP-B1-25 dimer of the present invention - ⁇ -.
- PL standard phospholipid mixture
- FIG. 9 is a measurement of preterm rabbit lung volume as a function of pressure comparing a standard phospholipid mixture (PL) - ⁇ -, Survanta - ⁇ -, the SP-B1-25 monomer - ⁇ -, and the SP-B1-25 dimer of the present invention - ⁇ -.
- PL standard phospholipid mixture
- the invention is a new synthetic SP-B peptide analog that may be used as a component of a pharmaceutical composition comprised of a surfactant-peptide dispersion for RDS therapy.
- the SP-B1-25 dimer is synthesized by covalently linking N-terminal domains of human SP-B that comprise selected active sites of the protein with a variable sized spacer that links an amino acid (Cys 8 in the preferred embodiment) of one peptide monomer to another amino acid (Cys 8) of the second peptide, as in FIG. 3.
- These covalently linked peptides form a dimer that mimics a portion of the secondary structure of native SP-B, thus retaining the desirable biological activities of native pulmonary surfactant.
- the dimer comprised of N-terminal fragments may have substantially the same amino acid sequences as the native composition, or may be a variant thereof (see e.g., the Cys 11 ⁇ Ala 11 variant of FIG. 3) and is smaller than the full-length native protein due to a truncation from the C-terminal end.
- the amino acid sequence and intramolecular linking of the dimer of the invention are designed to enhance formation of a peptide-lipid network in vivo, i.e., at the air/liquid interface of the lung, that enhances the existence of buckled and flat monolayers and lowers surface tension as observed in the native protein.
- the composition of the invention possesses certain properties that are superior to both native human SP-B and naturally derived surfactant therapies. Unlike the proteins extracted from animal tissue, the proposed method of synthesizing the surfactant minimizes the risk of contamination by other compounds and microorganisms. The method also is more economic as compared to isolating native and recombinant SP-B.
- the SP-B1-25 dimer is less water-soluble and more surface active than other SP-B peptides, such as the SP-B monomer (See FIG. 2), which leads to better retention of the dimer at the alveoli membrane interface.
- the SP-B1-25 dimer also has an enhanced shelf life and is highly resistant to lung surfactant inhibitors.
- compositions of the present invention are prepared by using a standard synthesis procedure according to the amino acid sequence of native SP-B as seen in FIG. 1.
- native human SP-B is a constituent of pulmonary surfactant-associated proteins that promote alveolar stability by lowering surface tension at the air-liquid interface in the peripheral air spaces of the lung.
- Native SP-B protein is a 17 k Da dimeric protein produced by the alveolar type II cells and is formed from a 381 amino acid precursor.
- Human SP-B is a 79 residue polypeptide, although certain published reports place the total length within the range of 78-80 residues.
- Native SP-B has a C-terminal methionine and contains seven cysteine residues.
- Human SP-B has three intrachain disulfide bridges, linking Cys 8 to Cys 77 , Cys 11 to Cys 71 , and Cys 35 to Cys 46 .
- the human SP-B subunit exists as a disulfide-linked homodimer having a interchain disulfide bridge at Cys 48 .
- the disulfide-mediated interaction between remote regions of the native polypeptide have an undetermined result on the conformational state of both the N- and C-terminal regions.
- SP-B's main function is to lower the surface tension by inserting lipids into the air/liquid interface of the lung and SP-B has been observed to increase the rate of spreading of surfactant from the aqueous phase to a phospholipid monolayer along the air water interface of the alveolus, partially by destabilization of the lipid bylayer.
- SP-B has a frequency of intermittent, highly-charged residues, including both hydrophylic and hydrophobic regions. The interrelationship between hydrophilic and hydrophobic regions causes stabilization of a phospholipid layer which resists the tendency of alveolar collapse.
- a peptide analog of the known SP-B primary sequence is synthesized by covalently linking constituent N-terminal SP-B residues 1-25 with a variable size spacer, preferably a disulfide link.
- the resulting peptide analogs interact with lung membranes and have the same secondary conformation as the native SP-B peptide contained in pulmonary surfactant-associated lipids.
- the peptide-lipid network formed in the surfactant lipids by administering the SP-B1-25 dimer of the present invention enhances the co-existence of buckled and flat monolayers in the same fashion as the native SP-B protein.
- the SP-B1-25 dimer optimizes the microstructure of surfactant dispersions by inducing a network of peptide-rich domains in surfactant lipid mono-and biolayers that yield buckled molecular structures that enhance the reversible spreading of the dispersion, as can be demonstrated both in vivo and in vitro.
- the SP-B1-25 dimer is less water soluble and more surface active than the native peptide, the protein analogs of the invention exhibit superior biochemical properties including solubility and retention at the air-liquid interface, and higher activity.
- compositions of the present invention are formulated and stored by known aseptic techniques and may contain physiologically compatible carriers or solvents and preferably contain between 95% and 98.5% lipids by weight percent in addition to the peptide analog of SP-B described herein.
- Suitable lipids include dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine (PC), cardiolipin (CL), phosphatidyl glycerol (PG), phosphatidyl serine (PS), fatty acid (FA), and triglyceride (TG).
- DPPC dipalmitoylphosphatidylcholine
- PC phosphatidylcholine
- C cardiolipin
- PG phosphatidyl glycerol
- PS phosphatidyl serine
- FA fatty acid
- TG triglyceride
- PC comprises approximately 80% of the phospholipids, about 40-50% of which is DPPC. The remaining lipids are present in minor
- the lipids composition When formulated in a liquid the lipids composition may be approximately 25 mg lipids/ml and may include ovine or bovine SP-C.
- the formulation may include liposomes, manufactured by conventional means, and may incorporate antioxidants or other therapeutic agents and may include diagnostic products such as imaging agents.
- the SP-B1-25 monomer, of which the present invention is comprised may be synthesized by known chemical techniques.
- the SP-B1-25 monomer peptide (FIG. 2) is synthesized on a 0.25 mmol scale with an Applied Biosystems model 431A peptide synthesizer using a FastMocTM strategy. Fields, C.
- HBTU Activation for Automated Fmoc Solid-Phase Peptide Synthesis Peptide Res. 4:95-101.
- the peptides are synthesized with prederivatized Fmoc-Gly resin (Calbiochem-Nova, La Jolla) or PEG-PA resin (Perceptive Biosystems, Old Connecticut Path, Mass.) and are single coupled for all residues.
- Purification of crude peptide product is by reverse-phase High Performance Liquid chromatography with a Vydac reverse phase C8-column (Vydac, Hesperia, Calif.) using a linear gradient of water:acetonitrile (0 to 100% acetonitrile with 0.1% trifluoroacetic acid as anion pairing agent) over a period of one hour.
- Purified peptide is twice freeze dried at a concentration of 5 mg peptide/ml from acetonitrile: 10 mM HCl solutions to remove acetate counterions that interfere with activity, and in vivo-in vitro measurements.
- the molecular mass of the monomeric SP-B 1-25 peptide is confirmed by fast atom bombardment electrospray mass spectroscopy (See FIG. 4).
- the complete sequence of the human SP-B manomer may be determined by reference to the Protein Data Bank—PDB-IDFW.
- the sequence of non-human mammalian SP-Bs may be determined by conventional means and the synthesis of the peptide analog of the invention based on the mammalian sequence.
- the SP-B 1-25 (Cys-11 ⁇ Ala-11) variant monomer is first reduced with 100 mM DDT (dithiothreitol) in TFE (trifluoroethanol):10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) at a concentration of 1 mg peptide per ml solution for 12 hours prior to oxidation.
- TFE trifluoroethanol
- the peptide solution is then passed through a Sephadex P-10 size exclusion column using TFE (trifluoroethanol):10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) to remove reducing agent prior to oxidation—disulfide formation.
- the isolated peptide solution is then freeze-dried overnight to remove solvent.
- the dry peptide powder is dissolved in TFE (trifluoroethanol): 10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) at a concentration of 1-2 mg peptide/ml and stirred vigorously for 24 hours to facilitate the air-mediated oxidation of the SP-B1-25 (Cys-11 ⁇ Ala-11) variant monomer to form a Cys8-Cys8 disulfide linked SP-B 1-25 (Cys-11 ⁇ Ala-11) variant disulfide linked homodimer.
- the molecular mass of the monomeric SP-B1-25 peptide is confirmed by electrospray mass spectroscopy (FIG. 4) and indicates that the yield of dimeric product to be essentially 100%.
- the homodimer peptide is then freeze-dried to remove the organic solvent prior to formulation with lipid.
- SP-B1-25 monomer can be produced by known recombinant DNA techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual, 1989; see also review of recombinant biology in Methods in Enzymology, vol. 185, Goeddel, D. V., ed, 1990; Towbin J A, Herz. 18:213-221, 1993).
- This technology allows directed synthesis of a protein in host cells that normally do not express the selected protein.
- cells are transfected with an expression vector containing the DNA encoding the mammalian monomer SP-B-25. Under appropriate growth conditions, the transformed host cells synthesize the SP-B1-25 polypeptide, which can be isolated from the cells or from the growth medium.
- Host cells suitable for the recombinant production of monomer SP-B 1-25 comprise prokaryotic cells such as strains of E. coli , Bacillus or Pseudomonas (Kung, H.-F., M. Bvidk, V. Manne, S. Yamazaki and E. Garcia, Curr. Topics in Cell. Reg. 26: 531-542, 1995) or unicellular eukaryotic cells as yeast Saccharomyces cerevisiae (Bemis, L. T., F. J. Geske and R. Strange, Methods Cell Biol., 46: 139-151, 1995).
- prokaryotic cells such as strains of E. coli , Bacillus or Pseudomonas (Kung, H.-F., M. Bvidk, V. Manne, S. Yamazaki and E. Garcia, Curr. Topics in Cell. Reg. 26: 531-542, 1995) or unicellular eukaryotic cells as yeast Saccharomy
- Host cells for recombinant production may also be derived from multicellular eukaryotes comprising invertebrates as insects ( Spodoptera frugiperda Sf9 cells) (Altmann F., E. Staudacher, I B Wilson, and L Marz, Glycoconj J., 16: 109-123,1999) and vertebrate cells, including numerous mammalian cell lines comprising mouse fibroblasts, chinese hamster ovary cells (CHO/ ⁇ DHFR)(Urlaub and Chasin, P.N.A.S.
- Plant biotechnology offers many advantages for efficient production of heterologous polypeptides, and this approach may be useful for production of monomer SP-B1-25 (see also Plant Technology: New Products and Applications, John Hammond, et al., eds., Springer, N.Y., 1999).
- the appropriate choice of host cell is determined by what is efficient and required for the accurate expression, processing and recovery of monomer SP-B1-15.
- the expression vector for production of recombinant monomer SP-B1-25 is constructed by inserting into a chosen vector the DNA encoding SP-B 1-25 and any nucleic acid sequences required for its propagation, expression and recovery from the host cell. These sequences comprise a replication origin, selection marker, promoter, ribosome binding site, enhancer sequences, RNA splice sites, transcription termination sites, and any sequence necessary for targeting, expression and recovery.
- the nucleic acids are inserted into the vector using standard recombinant DNA techniques (Sambrook et al, 1989). If amplification is necessary, the techniques for polymerase chain reaction (PCR) are clearly described (Innis, et al., Biotechnology 24:6-10, 1992).
- a variety of expression vectors comprising plasmids, phage particles, retroviruses or simply a genomic insert, are readily available that would be appropriate for the expression of a polypeptide such as monomer SP-B1-25 in the chosen host cell system.
- expression vectors are described for E. coli (Shatzman, A. R. and M. Rosenberg, Ann. N.Y. Acad. Sci., 840: 233-248, 1998), yeast (Bemis, supra. 1995), and mammalian cells (Werner, R G, W. Noe, K. Kopp and M. Schluter, Arzneimitt. 48:870-880, 1998).
- the SP-B1-25 dimer of the present invention may be formulated in a biocompatible composition containing synthetic surfactant lipid dispersions for administration to a human patient to treat respiratory disorders, including particularly respiratory distress syndrome.
- SP-B 1-25 (Cys-11 ⁇ Ala-11) variant disulfide linked homodimer is formulated with synthetic surfactant lipids by co-solvating the peptide (3% by wt) with synthetic surfactant lipids in chloroform:methanol (1:1, v:v).
- the synthetic surfactant lipid dispersion composition is DPPC (dipalmitoyl phosphatidycholine), has POPG (1-palmitoyl-2-oleoyl phosphatidyl glycerol):PA (palmitic acid) (66:22:9, wt %) (16) and has a final concentration of 25 mg lipids/ml PBS (phosphate buffered saline).
- DPPC dipalmitoyl phosphatidycholine
- POPG 1-palmitoyl-2-oleoyl phosphatidyl glycerol
- PA palmitic acid
- the chloroform-methanol-lipid peptide solution in a 20 ml screw cap vial is dried under nitrogen gas at 25° C. and stored in the refrigerator at 5° C. for 12 hours to cure (form a gel-like suspension).
- the cured lipid-peptide dispersion is then freeze-dried to remove the aqueous solvent and rehydrated with Milli-Q grade water followed by two more cycles of heating, low-temperature curing, and freeze-drying before final hydration and storage at 5° C. to use.
- Circular Dichroism (CD) measurements are made with an AVIV 62DS spectropolarimeter (AVIV Associates, Lakewood, N.J.).
- the AVIV 62DS is fitted with a thermoelectric temperature controller and the sample temperature maintained at 25° C.
- Peptide-solvent solutions are measured in 0.1 mm light path demountable cells scanned from 250 nm to 195 nm at a rate of 10 nm/min and a sample interval of 0.2 nm.
- the instrument is routinely calibrated with (+)-10-camphorsulfonic acid (1 mg/ml) and a 1-mm path length cell (Johnson, 1990 Johnson, W. C. J.
- the secondary structure of the SP-B 1-25 (Cys-11 ⁇ Ala-11) variant disulfide linked homodimer is accessed in two different structure promoting membrane mimic environments using Circular Dichroism spectroscopy.
- TFE:phosphate buffer, 1:1, v:v (FIG. 5)
- the SP-B 1-25 dimer had a spectral dichroic minima at 222 and 208 nm and a dichroic maximum near 193 nm typical of a peptide having a dominant helical content.
- the spectral figure at 222 nm suggests the peptide assumed about 41% helical conformations.
- N-terminal segment of a mammalian SP-B protein as the basis for a therapeutic composition is based on the capability of the N-terminal segment to mimic many of the in vitro-in vivo functions of the full-length SP-B protein.
- the N-terminal segment may lack the respreadability of lipids observed with the full length protein and, in addition, may exhibit some hemolytic activity not seen with full length SP-B. Therefore, pursuant to this invention, several modifications may be made in both the primary sequence and the tertiary structure.
- Cys-11 was replaced with alanine (Cys surrogate residue SP-B (Cys-11 ⁇ Ala-11) variant monomer) so as to provide a possible disulfide linkage at Cys-8 to a second SP-B 1-25 (Cys-11 ⁇ Ala-11) variant having a single Cys-8, forming a unique SP-B 1-25 (Cys-11 ⁇ Ala-11) variant disulfide linked homodimer (FIG. 3). Additional structural/functional relationships should be accommodated when synthesizing the N-terminal SP-B analogs of the present invention.
- the resulting pharmaceutical formulation comprised of an N-terminal SP-B analog must be capable of maintaining a coherent, tightly packed monolayer that avoids alveolar collapse during expiration. Accordingly, positively charged residues in the SP-B analog may lead to higher collapse pressures and lower surface tensions. See Longo, M. L., Bisagno, A. M., Zasadzinski, J. A. N., Bruni, R. and Waring, A. J., A Function of Lung Surfactant Protein SP-B, Science 261:453-456, Jul. 23, 1993.
- the secondary conformations and surface activities of SP-B analogs or derivatives should correlate to an ⁇ -helical structure that maintains the ability of the peptide to interact with lipids and with the surface activity of peptide/lipid dispersions.
- Amino acid substitutions that alter either the charge or the hydrophobicity of the analog tend to lower the helical content and reduce the association of the N-terminal segment with the lipid dispersion. See Bruni, R., Taeusch, H. W., and Waring, A. J., Surfactant protein B: Lipid interactions of synthetic peptides representing the amino-terminal amphipathic domain, Proc. Natl. acad. Sci. USA 88:7451-7455, August 1991.
- SP-B analogs should be designed to optimize their function in accord with the native SP-B protein based on topography, charge distribution, contribution and physical or chemical properties as described in Gordon, L. M., Horvath, S., Longo, M. L., Zasadzinski, J. A. N., Taeusch, H. W., Faull, K., Leung, C., and Waring, A. J., Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments, Protein Science, 5:1662-1675, 1996.
- the peptide analog of this invention is shorter than the native 79 residue peptide chain.
- the SP-B 1-25 homodimer is one example of a molecule that is shorter than the native protein, but that retains the critical function as described herein.
- Other N-terminal molecules may be created by truncation from the C-terminal end with preservation of the functional properties described above. Therefore, the invention contemplates molecules from between approximately 25 to 77 residues, preferably formed as a homodimer, and all integral values between 25 and 77.
- other molecules having a length between 40 and 50 may yield a conformation preserving the function of the native SP-B protein.
- PL phospholipid mixture
- DPPC dipalmitoyl phosphatidylcholine
- POPG 2-oloeyl phosphatidylglycerol
- PA palmitic acid
- Rats were anesthetized with 35 mg/kg of pentobarbital sodium and 80 mg/kg of ketamine by intraperitoneal injection. After placement of a tracheal cannula, the rats were supported on a rodent ventilator (Harvard Apparatus, South Natick, Mass.) with 100% oxygen, a tidal volume of 7.5 mL/kg and a rate of 60/min. An arterial line was placed in the abdominal aorta for serial measurements of arterial blood gases and the rats were paralyzed with 2 mg/kg of pancuronium bromide intravascularly. Only animals with PaO 2 values >400 Torr while ventilated with 100% oxygen were included in the experiments.
- Arterial blood gases, tidal volume, peak inspiratory pressure (PIP), and positive end-expiratory pressure (PEEP) were determined at 15 minute intervals throughout the experiment.
- the lung volume measured at a pressure of 5 cm H 2 O (V 5 ) was issued as an index of stability at low lung volumes, whereas lung volumes at a pressure of 30 cm H 2 O (V 30 ) were assumed as total lung capacity.
- Each treatment group consisted of 8 animals. All experiments were performed humanely and with the approval of the Animal Care and Use Committee of the Harbor-UCLA Medical Center Research and Education Institute.
- the arterial/Alveolar PO 2 ′ (a/A) ratio was calculated using the PaO 2 PaCO 2 , and FiO 2 values and used to express oxygenation. Oxygenation and data from the pressure-volume curves are given as mean ⁇ SEM with 8 rats in each experimental group.
- Groups of 8 rats were lavaged until surfactant-deficiency and were than treated with one of 4 surfactant preparations, i.e., PL, B1-25 dimer, B1-25 monomer, or Survanta®. Rats treated with B1-25 dimer surfactant reached the highest oxygenation values (arterial/Alveolar PO 2 ratios) and rats treated with PL the lowest (FIG. 7).
- the surfactant preparations could be ranked as follows: B1-25 dimer>Survanta®>B1-25 monomer>PL surfactant.
- the trachea of each newborn was exposed through a small incision in the anterior neck, and a short tube from an 18-gauge needle was tied in the trachea.
- Each rabbit was ventilated with 100% oxygen using an anesthesia bag and manometer for about five breaths and transferred to a temperature-controlled ventilator-plethysmograph system that permits the simultaneous ventilation of 10 newborn rabbits.
- the plethysmographs are a serial of 10 clear Plexiglas boxes, temperature-controlled at 37° C., that are connected to 10 rebreathing circuits containing soda lime and driven by a Sechrist infant ventilator (Sechrist Industries, Anaheim, Calif.).
- the rabbits were ventilated with 100% oxygen at a rate of 40 breaths/minute with a 1:1 inspiratory-to-expiratory time ratio. No positive end-expiratory pressure was used to avoid the air trapping that seems to occur in preterm rabbits.
- the initial peak inspiratory pressure was 30 cm H 2 O and peak pressure was adjusted individually to achieve a tidal volume of about 10 mL/kg as measured with a pneumotachometer (Validyne, Northridge, Calif.) and a multichannel recorder (Gould Inc., Cleveland, Ohio). Peak inspiratory pressure was limited at 35 cm H 2 O to avoid pneumothorax. Dynamic compliance was calculated by dividing tidal volume by peak inspiratory pressure and the body weight in kg (mL/kg/cm H 2 O) and monitored every 15 minutes.
- All preterm rabbits were treated with 100 mg/kg of an experimental surfactant after insertion of the endotracheal tube and prior to bagging. After 60 minutes of ventilation, each rabbit was sacrificed by an administration of an intrathecal injection of lidocaine and was disconnected from the ventilator. Pressure-volume curves were measured in situ to define lung mechanics. Lungs were inflated and deflated using a bidirectional Harvard pump coupled to a 10-mL glass syringe, and pressure was continuously recorded on a Gould multichannel recorder. Each pressure-volume curve was corrected for the compliance of the system by subtracting the pressure-volume curve of the pump/syringe unit carried out before each curve.
Abstract
A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.
Description
- [0001] This invention was made in part from government support under Grant Nos. RO1 HL 55543 and RO1 HL 51177 from the National Institute of Health (NIH) of the United States. The U.S. Government may have certain rights in this invention.
- The present invention relates generally to a therapeutic pharmaceutical composition for the treatment of respiratory disease, including particularly Respiratory Distress Syndrome (RDS) comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.
- The human lung is composed of a large number of small air sacs, called alveoli, in which gases are exchanged between the blood and the air spaces of the lungs. In healthy individuals, this exchange is mediated by the presence of a protein-containing surfactant complex. Lung surfactant complex is composed primarily of lipid and contains a minor component of various proteins. An absence of adequate levels of this complex results in malfunction of the lung. This syndrome is called Respiratory Distress Syndrome (RDS). Adult RDS is correlated with an absence or dysfunction of the lung surfactant at the alveoli membrane where the gas exchange occurs. The adult disease results from lung insults such as diffuse infections, aspiration of the gastric contents or water, inhalation of irritants and toxins and pulmonary edema arising from such sources as narcotic overdose. The syndrome is also common in premature infants and is associated with immaturity and low birth weight. Of those pre-term infants afflicted, approximately 10% die. Infantile respiratory distress syndrome is the leading cause of death in the first twenty-eight days of life.
- Patients with RDS exhibit either abnormal quantities of lung surfactant, an abnormal composition of lung surfactant, or both. Successful treatments focus on replacing surfactant levels and composition to the normal range through surfactant replacement therapy. At the alveolar level, lung surfactant functions prevent excessive accumulation of liquid within the alveolar airspace and stabilize the alveoli and small airways against collapse. A lung surfactant deficiency results in the collapse of the alveoli causing respiratory distress. Surfactant replacement therapy can be used either prophylactically or as rescue treatment for patients with clinical signs of RDS.
- The composition of native lung surfactant is lipid (approximately 90%-97%) and various proteins (approximately 10%). The primary lipid type is phospholipid and constitutes 97% of the total lipid. 80% of this phospholipid is phosphatidylcholine (PC) and 10% is phosphatidyglycerol (PG). 70-80% of the phospholipid acyl chains are saturated. The major lipid is dipalmitoylphosphatidylcholine (DPPC). Four surfactant-associated proteins are known to exist: two are glycoproteins, SP-A and SP-D, and two are small hydrophobic proteins, SP-C and SP-B.
- Human lung surfactant contains a hydrophobic SP-B peptide, which is usually present as a dimer. The SP-B functions by reducing the surface tension of alveoli to prevent collapse of the lung air sacs, thereby preventing respiratory distress. In the past, surfactant replacement therapies focused on using the lipid components alone. It was later found that the therapy's performance was greatly improved by the use of the apoprotein in similar proportion to native human surfactant.
- Current RDS therapies generally attempt to either utilize natural SP-B or SP-C from other mammals or to synthesize a protein with the functional equivalent of human SP-B. Of the commercially available treatments, the majority utilize natural or modified-natural lung surfactants instead of synthetic surfactants. The natural, animal derived, lung surfactants are harvested from animal lungs either by organic solvent extracts of lung lavage or by organic solvent extracts of minced lungs. The following are commercially available lung surfactants: Curosurf, manufactured by Cheisi Farmeceutici of Italy, is such a natural lung surfactant derived from porcine lung lavage extract. Curosurf contains DPPC in similar proportion to human surfactant and SP-B & SP-C. Another natural lung surfactant, Infasurf, manufactured by Forest Laboratories, is a natural surfactant extract from calf lung lavage. Infasurf is also comprised of phospholipids and SP-B & SP-C. Another commercially available natural lung surfactant is Survanta®, manufactured by Abbott Labs, a chemically modified natural bovine lung extract. The only synthetic lung surfactant therapy commercially available, Exosurf, manufactured by Glaxo Wellcome, is a synthetic protein free surfactant composed of eighty-five percent DPPC, nine-percent hexadecanol and six-percent tyloxapol. Surfactant replacement therapy can be used either prophylactically or as a rescue treatment for patients with clinical signs of RDS.
- The present invention includes a pharmaceutical composition of synthetic peptides used to treat respiratory disorders. The composition may also be added to existing treatments to enhance the biological activity of existing pulmonary surfactant dispersions for the treatment of RDS. The invention preferably provides a composition of novel synthetic peptide analogs of SP-B that mimic the active site of native Surfactant Protein B (SP-B). The composition of the invention may be used to supplement naturally derived lung surfactants or to formulate synthetic lung surfactant lipid-peptide dispersions. See Walther, F. J., Hernandez-Juviel, J., Bruni, R., Waring, A. J., “Spiking Survanta with Synthetic Surfactant Peptides Improves Oxygenation in Surfactant-deficient Rats,” Am. J. Respir. Crit. Care Med., Vol. 156:855-861, 1997. Unlike protein free formulations, the synthetic peptide of the present invention mimics the active site of the SP-B protein and creates a synthetic analog of these amino acids to augment the properties of the native proteins.
- The SP-B analogs of the present invention are based on the known primary sequence of native mammalian SP-B and in a preferred embodiment, human SP-B. Specifically, in one preferred embodiment, a covalently linked dimer of the constituent N-terminus SP-B domain (amino acids 1-25), herein referred to as the SP-B1-25 dimer, may replace or supplement full length proteins currently used to treat RDS. Because the human peptide is more effective than other natural SP-B derived from animal sources, the creation of a synthetic peptide that mimics human SP-B is more efficacious in the treatment of RDS than natural surfactants derived from animals. Furthermore, the dimeric SP-B1-25 exhibits advantageous physical and chemical characteristics in analyses that reflect the desired properties of surface tension at the air/liquid interface of the lung. The SP-B1-25 dimer can be formulated in therapeutic compositions for the treatment of respiratory disorders, and can be used in methods designed to treat respiratory disorders when clinically indicated.
- FIG. 1 is the amino acid sequence in three letter code of native human surfactant protein B (SP-B).
- FIG. 2 is the amino acid sequence in one letter code of SP-B1-25 of native human SP-B1-25 and the
Cys 11→Ala 11 variant monomer. - FIG. 3 is the amino acid sequence in one letter code of the SP-B1-25
Cys 11→Ala 11 variant disulfide linked homodimer of the present invention. - FIG. 4 is a fast atom bombardment electrospray mass spectrograph of the SP-B1-25.
- FIG. 5 is a Circular Dichroism (CD) spectrum of SP-B1-25 dimer in a structure promoting solvent system of trifluoroethanolamine (TFE):phosphate buffer.
- FIG. 6 is a CD spectrum of SP-B1-25 dimer in palmitoylolsoyl phosphatidyl glycerol (POPG) liposomes with phosphate buffered saline (PBS) palmitoyl olcoyl phosphatidyl glycerol buffer.
- FIG. 7 is a measurement of oxygenation in lavaged rat lungs comparing a standard phospholipid mixture (PL)-λ-, Survanta -σ-, the SP-B1-25 monomer -∇-, and the SP-B1-25 dimer of the present invention -ν-.
- FIG. 8 is a measurement of lavaged rat lung volume as a function of pressure comparing a standard phospholipid mixture (PL) -λ-, Survanta -σ-, the SP-B1-25 monomer -∇-, and the SP-B1-25 dimer of the present invention -ν-.
- FIG. 9 is a measurement of preterm rabbit lung volume as a function of pressure comparing a standard phospholipid mixture (PL) -λ-, Survanta -σ-, the SP-B1-25 monomer -∇-, and the SP-B1-25 dimer of the present invention -ν-.
- The invention is a new synthetic SP-B peptide analog that may be used as a component of a pharmaceutical composition comprised of a surfactant-peptide dispersion for RDS therapy. In a preferred embodiment, the SP-B1-25 dimer is synthesized by covalently linking N-terminal domains of human SP-B that comprise selected active sites of the protein with a variable sized spacer that links an amino acid (Cys 8 in the preferred embodiment) of one peptide monomer to another amino acid (Cys 8) of the second peptide, as in FIG. 3. These covalently linked peptides form a dimer that mimics a portion of the secondary structure of native SP-B, thus retaining the desirable biological activities of native pulmonary surfactant. The dimer comprised of N-terminal fragments may have substantially the same amino acid sequences as the native composition, or may be a variant thereof (see e.g., the
Cys 11→Ala 11 variant of FIG. 3) and is smaller than the full-length native protein due to a truncation from the C-terminal end. Like native SP-B, the amino acid sequence and intramolecular linking of the dimer of the invention are designed to enhance formation of a peptide-lipid network in vivo, i.e., at the air/liquid interface of the lung, that enhances the existence of buckled and flat monolayers and lowers surface tension as observed in the native protein. - The composition of the invention possesses certain properties that are superior to both native human SP-B and naturally derived surfactant therapies. Unlike the proteins extracted from animal tissue, the proposed method of synthesizing the surfactant minimizes the risk of contamination by other compounds and microorganisms. The method also is more economic as compared to isolating native and recombinant SP-B. The SP-B1-25 dimer is less water-soluble and more surface active than other SP-B peptides, such as the SP-B monomer (See FIG. 2), which leads to better retention of the dimer at the alveoli membrane interface. The SP-B1-25 dimer also has an enhanced shelf life and is highly resistant to lung surfactant inhibitors.
- The compositions of the present invention are prepared by using a standard synthesis procedure according to the amino acid sequence of native SP-B as seen in FIG. 1. As noted above, native human SP-B is a constituent of pulmonary surfactant-associated proteins that promote alveolar stability by lowering surface tension at the air-liquid interface in the peripheral air spaces of the lung. Native SP-B protein is a 17 k Da dimeric protein produced by the alveolar type II cells and is formed from a 381 amino acid precursor. Human SP-B is a 79 residue polypeptide, although certain published reports place the total length within the range of 78-80 residues. Native SP-B has a C-terminal methionine and contains seven cysteine residues. Human SP-B has three intrachain disulfide bridges, linking Cys8 to Cys77, Cys11 to Cys71, and Cys35 to Cys46. In its native form, the human SP-B subunit exists as a disulfide-linked homodimer having a interchain disulfide bridge at Cys48. In native SP-B, the disulfide-mediated interaction between remote regions of the native polypeptide have an undetermined result on the conformational state of both the N- and C-terminal regions.
- SP-B's main function is to lower the surface tension by inserting lipids into the air/liquid interface of the lung and SP-B has been observed to increase the rate of spreading of surfactant from the aqueous phase to a phospholipid monolayer along the air water interface of the alveolus, partially by destabilization of the lipid bylayer. SP-B has a frequency of intermittent, highly-charged residues, including both hydrophylic and hydrophobic regions. The interrelationship between hydrophilic and hydrophobic regions causes stabilization of a phospholipid layer which resists the tendency of alveolar collapse.
- Pursuant to the present invention, a peptide analog of the known SP-B primary sequence is synthesized by covalently linking constituent N-terminal SP-B residues 1-25 with a variable size spacer, preferably a disulfide link. The resulting peptide analogs interact with lung membranes and have the same secondary conformation as the native SP-B peptide contained in pulmonary surfactant-associated lipids. The peptide-lipid network formed in the surfactant lipids by administering the SP-B1-25 dimer of the present invention enhances the co-existence of buckled and flat monolayers in the same fashion as the native SP-B protein. Also, the SP-B1-25 dimer optimizes the microstructure of surfactant dispersions by inducing a network of peptide-rich domains in surfactant lipid mono-and biolayers that yield buckled molecular structures that enhance the reversible spreading of the dispersion, as can be demonstrated both in vivo and in vitro. However, because the SP-B1-25 dimer is less water soluble and more surface active than the native peptide, the protein analogs of the invention exhibit superior biochemical properties including solubility and retention at the air-liquid interface, and higher activity.
- Pharmaceutical compositions of the present invention are formulated and stored by known aseptic techniques and may contain physiologically compatible carriers or solvents and preferably contain between 95% and 98.5% lipids by weight percent in addition to the peptide analog of SP-B described herein. Suitable lipids include dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine (PC), cardiolipin (CL), phosphatidyl glycerol (PG), phosphatidyl serine (PS), fatty acid (FA), and triglyceride (TG). PC comprises approximately 80% of the phospholipids, about 40-50% of which is DPPC. The remaining lipids are present in minor concentrations.
- When formulated in a liquid the lipids composition may be approximately 25 mg lipids/ml and may include ovine or bovine SP-C. The formulation may include liposomes, manufactured by conventional means, and may incorporate antioxidants or other therapeutic agents and may include diagnostic products such as imaging agents.
- Solid Phase Synthesis Purification and Characterization of the SP-B1-25
Cys 11→Ala 11 Variant Monomer. - The SP-B1-25 monomer, of which the present invention is comprised, may be synthesized by known chemical techniques. (Glasser, et al., Proc. Natl. Acad. Sci. U.S.A. 84:4007, 1987 Jacobs, et al., J. Biol. Chem. 262:9808, 1987; Floros, et al., J. Biol. Chem. 261:9029, 1986; White, et al., Nature 317:361, 1985; Whitsett, et al., Pediatr. Res. 19:501, 1985; Warr, et al., Proc. Natl. Acad. Sci. U.S.A. 84:7915, 1987; Hawgood, et al., Proc. Natl. Acad. Sci. U.S.A. 84:66, 1987; Glasser, et al., J. Biol. Chem. 263:9, 1988, Glasser, et al., supra, J. Biol. Chem. 263: 10326, 1988; and Jobe et al., Am. Rev. Resp. Dis. 136:1032, 1987). Preferably, however, the SP-B1-25 monomer peptide (FIG. 2) is synthesized on a 0.25 mmol scale with an Applied Biosystems model 431A peptide synthesizer using a FastMoc™ strategy. Fields, C. G., Lloyd, D. H. Macdonald, R. L., Ottenson, K. M., and Noble, R. L. 1991. “HBTU Activation for Automated Fmoc Solid-Phase Peptide Synthesis,” Peptide Res. 4:95-101. The peptides are synthesized with prederivatized Fmoc-Gly resin (Calbiochem-Nova, La Jolla) or PEG-PA resin (Perceptive Biosystems, Old Connecticut Path, Mass.) and are single coupled for all residues.
- Purification of crude peptide product is by reverse-phase High Performance Liquid chromatography with a Vydac reverse phase C8-column (Vydac, Hesperia, Calif.) using a linear gradient of water:acetonitrile (0 to 100% acetonitrile with 0.1% trifluoroacetic acid as anion pairing agent) over a period of one hour. Purified peptide is twice freeze dried at a concentration of 5 mg peptide/ml from acetonitrile: 10 mM HCl solutions to remove acetate counterions that interfere with activity, and in vivo-in vitro measurements. The molecular mass of the monomeric SP-B 1-25 peptide is confirmed by fast atom bombardment electrospray mass spectroscopy (See FIG. 4). The complete sequence of the human SP-B manomer may be determined by reference to the Protein Data Bank—PDB-IDFW. The sequence of non-human mammalian SP-Bs may be determined by conventional means and the synthesis of the peptide analog of the invention based on the mammalian sequence.
- Formulation of the SP-B 1-25 (Cys-11→Ala-11) Variant Disulfide Linked Homodimer of the Present Invention.
- The SP-B 1-25 (Cys-11→Ala-11) variant monomer is first reduced with 100 mM DDT (dithiothreitol) in TFE (trifluoroethanol):10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) at a concentration of 1 mg peptide per ml solution for 12 hours prior to oxidation. The peptide solution is then passed through a Sephadex P-10 size exclusion column using TFE (trifluoroethanol):10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) to remove reducing agent prior to oxidation—disulfide formation. The isolated peptide solution is then freeze-dried overnight to remove solvent. The dry peptide powder is dissolved in TFE (trifluoroethanol): 10 mM sodium phosphate buffer pH 7.5 (1:1, v:v) at a concentration of 1-2 mg peptide/ml and stirred vigorously for 24 hours to facilitate the air-mediated oxidation of the SP-B1-25 (Cys-11→Ala-11) variant monomer to form a Cys8-Cys8 disulfide linked SP-B 1-25 (Cys-11→Ala-11) variant disulfide linked homodimer. The molecular mass of the monomeric SP-B1-25 peptide is confirmed by electrospray mass spectroscopy (FIG. 4) and indicates that the yield of dimeric product to be essentially 100%. The homodimer peptide is then freeze-dried to remove the organic solvent prior to formulation with lipid.
- Alternatively, SP-B1-25 monomer can be produced by known recombinant DNA techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual, 1989; see also review of recombinant biology in Methods in Enzymology, vol. 185, Goeddel, D. V., ed, 1990; Towbin J A, Herz. 18:213-221, 1993). This technology allows directed synthesis of a protein in host cells that normally do not express the selected protein. To produce recombinant monomeric SP-1-25 protein, cells are transfected with an expression vector containing the DNA encoding the mammalian monomer SP-B-25. Under appropriate growth conditions, the transformed host cells synthesize the SP-B1-25 polypeptide, which can be isolated from the cells or from the growth medium.
- A wide variety of host cells are available for use in recombinant technology. Host cells suitable for the recombinant production of monomer SP-B 1-25 comprise prokaryotic cells such as strains ofE. coli, Bacillus or Pseudomonas (Kung, H.-F., M. Boublik, V. Manne, S. Yamazaki and E. Garcia, Curr. Topics in Cell. Reg. 26: 531-542, 1995) or unicellular eukaryotic cells as yeast Saccharomyces cerevisiae (Bemis, L. T., F. J. Geske and R. Strange, Methods Cell Biol., 46: 139-151, 1995). Host cells for recombinant production may also be derived from multicellular eukaryotes comprising invertebrates as insects (Spodoptera frugiperda Sf9 cells) (Altmann F., E. Staudacher, I B Wilson, and L Marz, Glycoconj J., 16: 109-123,1999) and vertebrate cells, including numerous mammalian cell lines comprising mouse fibroblasts, chinese hamster ovary cells (CHO/−DHFR)(Urlaub and Chasin, P.N.A.S. 77:4216, 1980), baby hamster kidney (9BHK, ATCC CCL 10); monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651) and human embryonic kidney cell line 293 (Tartaglia et al., P.N.A.S. 88: 9292-9296, 1991 and Pennica et al., J. Biol. Chem. 267:21172-21178, 1992).
- While bacteria and yeast have been standard recombinant host cells for over a decade, investigators have recently transformed cells from higher plants to express human recombinant proteins as antibodies (Hiatt, A. T. and J. K. Ma, Int. Rev. Immunol., 10: 139-152, 1993) and hemoglobin (Theisen, M. in Chemicals Via Higher Plant Bioengineering, F. Shahidi et al., eds, Plenum Publishers, NY, p. 211-220, 1999). Plant biotechnology offers many advantages for efficient production of heterologous polypeptides, and this approach may be useful for production of monomer SP-B1-25 (see also Plant Technology: New Products and Applications, John Hammond, et al., eds., Springer, N.Y., 1999). The appropriate choice of host cell is determined by what is efficient and required for the accurate expression, processing and recovery of monomer SP-B1-15.
- The expression vector for production of recombinant monomer SP-B1-25 is constructed by inserting into a chosen vector the DNA encoding SP-B 1-25 and any nucleic acid sequences required for its propagation, expression and recovery from the host cell. These sequences comprise a replication origin, selection marker, promoter, ribosome binding site, enhancer sequences, RNA splice sites, transcription termination sites, and any sequence necessary for targeting, expression and recovery. The nucleic acids are inserted into the vector using standard recombinant DNA techniques (Sambrook et al, 1989). If amplification is necessary, the techniques for polymerase chain reaction (PCR) are clearly described (Innis, et al., Biotechnology 24:6-10, 1992).
- A variety of expression vectors, comprising plasmids, phage particles, retroviruses or simply a genomic insert, are readily available that would be appropriate for the expression of a polypeptide such as monomer SP-B1-25 in the chosen host cell system. For example, expression vectors are described forE. coli (Shatzman, A. R. and M. Rosenberg, Ann. N.Y. Acad. Sci., 840: 233-248, 1998), yeast (Bemis, supra. 1995), and mammalian cells (Werner, R G, W. Noe, K. Kopp and M. Schluter, Arzneimitt. 48:870-880, 1998). For plants, Ti plasmids are delivered by Agrobacterium infection and viral vectors are also available (Hansen, G, and M. D. Chilton, in Plant Technology: New Products and Applications, H. Hammond et al., eds., Springer, p. 22-57, 1999). Verma et al. (J. Immunol. Methods, 216: 165-181, 1998) and Morrison (Ann. Rev. Immunol. 10: 239-265, 1992) discuss the relative advantages and disadvantages of various expression systems for the recombinant production of human proteins. In the appropriate expression system, the recombinant monomer SP-B1-25 can be synthesized and then isolated either from host cells or from the growth medium. Monomer SP-B1-25 is purified to homogeneity as described for chemically purified peptide, with modifications as required for the expression system selected.
- Formulation of a Therapeutic Composition Containing the SP-B1-25 Dimer (
Cys 11→Ala-11) Variant Disulfide Linked Homodimer and Synthetic Surfactant Lipid Dispersions. - The SP-B1-25 dimer of the present invention may be formulated in a biocompatible composition containing synthetic surfactant lipid dispersions for administration to a human patient to treat respiratory disorders, including particularly respiratory distress syndrome. Preferably, SP-B 1-25 (Cys-11→Ala-11) variant disulfide linked homodimer is formulated with synthetic surfactant lipids by co-solvating the peptide (3% by wt) with synthetic surfactant lipids in chloroform:methanol (1:1, v:v). The synthetic surfactant lipid dispersion composition is DPPC (dipalmitoyl phosphatidycholine), has POPG (1-palmitoyl-2-oleoyl phosphatidyl glycerol):PA (palmitic acid) (66:22:9, wt %) (16) and has a final concentration of 25 mg lipids/ml PBS (phosphate buffered saline). The chloroform-methanol-lipid peptide solution in a 20 ml screw cap vial is dried under nitrogen gas at 25° C. and stored in the refrigerator at 5° C. for 12 hours to cure (form a gel-like suspension). The cured lipid-peptide dispersion is then freeze-dried to remove the aqueous solvent and rehydrated with Milli-Q grade water followed by two more cycles of heating, low-temperature curing, and freeze-drying before final hydration and storage at 5° C. to use.
- Determination of the Secondary Structure of the SP-B 1-25 (Cys-11→Ala-1) Variant Disulfide Linked Homodimer.
- Circular Dichroism (CD) measurements are made with an AVIV 62DS spectropolarimeter (AVIV Associates, Lakewood, N.J.). The AVIV 62DS is fitted with a thermoelectric temperature controller and the sample temperature maintained at 25° C. Peptide-solvent solutions are measured in 0.1 mm light path demountable cells scanned from 250 nm to 195 nm at a rate of 10 nm/min and a sample interval of 0.2 nm. The instrument is routinely calibrated with (+)-10-camphorsulfonic acid (1 mg/ml) and a 1-mm path length cell (Johnson, 1990 Johnson, W. C. J. 1990, “Protein Secondary Structure and Circular Dichroism: A Practical Guide.” Proteins Struct. Funct. Genet. 7:205-214, and the ellipticity expressed as the mean residue ellipticity, θMRE (deg cm2 dmol−1). Peptide sample concentrations are determined by quantitative amino acid analysis (UCLA Micro Sequencing Facility, Los Angeles, Calif.). The percentage of α-helix conformation in the peptide is estimated using the formalism of Chen et al. Chen Y H, Yant J T, Chaus K H. 1974. “Determination of the Helix and β Form of Proteins in Aqueous Solution by Circular Dichroism.” Biochemistry 13:3350-3359. This approach assumes the maximum theoretical ellipticity for a given peptide or protein at 222 nm may be derived from the number of amino acid residues n, and the ellipticity at 222 nm of a helix of infinite length described by Equation (1).
- % α-helix=θ MRE222−[−39,500(1−(2.57/n))]deg cm2 dmol−1 (1)
- The secondary structure of the SP-B 1-25 (Cys-11→Ala-11) variant disulfide linked homodimer is accessed in two different structure promoting membrane mimic environments using Circular Dichroism spectroscopy. In TFE:phosphate buffer, 1:1, v:v (FIG. 5), a solvent system used to mimic membrane associating peptides and proteins, the SP-B 1-25 dimer had a spectral dichroic minima at 222 and 208 nm and a dichroic maximum near 193 nm typical of a peptide having a dominant helical content. Using the formalism of Chen et al. (1974 supra), the spectral figure at 222 nm suggests the peptide assumed about 41% helical conformations.
- Referring to FIG. 6, when the peptide is added to POPG liposomes (a major lipid component of surfactant lipid) the helical component is similar to that observed in the organic solvent system. Deconvolution of the spectra using the computer program suggests that the peptide assumed about 44.7% helix, 17.1% beta sheet, 28.2% beta turn and 10.0% disordered conformations in POPG surfactant lipid liposomes and are typical of the conformations observed for native proteins in organic solvent/water mixtures and synthetic SP-B peptides in this type of environment. [Lincomb Perczel, A., Park, K., Fasman, G. D., Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: A practical guide. Analytical Biochem 203:83-93, 1992] [Compare Perez-Gil, J., A. Cruz, Casals, C. Solubility of hydrophobic surfactant Structural studies on SP-B and SP-C in aqueous organic solvents and lipids. Biochim. Biophys Acta, 1168:261-270, 1993; Bruni, R., Taeusch, W., and Waring, A., “Surfactant protein SP-B: Lipid interactions of synthetic peptides representing the amino terminal amphipathic domain,” Proc. Nat. Acad. Sci. USA, 88:7451-7455 (1991); Gordon, L. M., Horvath S., Longo, M., Zasadzinski, J. A. N., Taeusch, H. W., Faull, K., Leung, C., and Waring, A. J., “Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments,” Protein Science 5:1662-1675 (1996)].
- Synthesis of Analogs or Derivatives of the SP-B1-25 Dimer Using the Molecular Design Rationale of the Present Invention.
- Although the preferred embodiment of the present invention has been described as the SP-B1-25
Cys 11→Ala-11 variant Cys 8-Cys8 disulfide linked homodimer, various derivatives or functional analogues thereof may be prepared without departing from the spirit of the invention. These derivatives or functional analogues may be designed according to the rationale of the present invention as described herein. - Selection of an N-terminal segment of a mammalian SP-B protein as the basis for a therapeutic composition is based on the capability of the N-terminal segment to mimic many of the in vitro-in vivo functions of the full-length SP-B protein. However, the N-terminal segment may lack the respreadability of lipids observed with the full length protein and, in addition, may exhibit some hemolytic activity not seen with full length SP-B. Therefore, pursuant to this invention, several modifications may be made in both the primary sequence and the tertiary structure. For example, emulation of the Saposin fold amphipathic helix-disulfide connectivity unique to the Saposin protein family including SP-B, Saposins, NK-lysin, Granulysin, Amoebapore, of the N-terminal segment to make it more closely emulate the in vitro-in vivo structure and function of the native SP-B proteins. [Liepinish, E., Andersson, M., Ruysschaert, J.-M., and Otting, G. (1997) “Saposin Fold Revealed by the NMR Structure of NK-Lysin.”: Nature. Struct. Biol. 4:793-795; Waring, A. J., Chen, Y., Faull, K. F., Stevens, R., Sherman, M. A., and Fluharty, A. L., “Porcine Cerebroside Sulfatide Activator Protein (SAP-B) Secondary Structure: CD, FTIR, and NMR Studies: Molecular Genetics and Metabolism 63:14-25 (1998).]
- In the preferred embodiment herein, Cys-11 was replaced with alanine (Cys surrogate residue SP-B (Cys-11→Ala-11) variant monomer) so as to provide a possible disulfide linkage at Cys-8 to a second SP-B 1-25 (Cys-11→Ala-11) variant having a single Cys-8, forming a unique SP-B 1-25 (Cys-11→Ala-11) variant disulfide linked homodimer (FIG. 3). Additional structural/functional relationships should be accommodated when synthesizing the N-terminal SP-B analogs of the present invention. For example, the resulting pharmaceutical formulation comprised of an N-terminal SP-B analog must be capable of maintaining a coherent, tightly packed monolayer that avoids alveolar collapse during expiration. Accordingly, positively charged residues in the SP-B analog may lead to higher collapse pressures and lower surface tensions. See Longo, M. L., Bisagno, A. M., Zasadzinski, J. A. N., Bruni, R. and Waring, A. J., A Function of Lung Surfactant Protein SP-B, Science 261:453-456, Jul. 23, 1993.
- Similarly, the secondary conformations and surface activities of SP-B analogs or derivatives should correlate to an α-helical structure that maintains the ability of the peptide to interact with lipids and with the surface activity of peptide/lipid dispersions. Amino acid substitutions that alter either the charge or the hydrophobicity of the analog tend to lower the helical content and reduce the association of the N-terminal segment with the lipid dispersion. See Bruni, R., Taeusch, H. W., and Waring, A. J., Surfactant protein B: Lipid interactions of synthetic peptides representing the amino-terminal amphipathic domain, Proc. Natl. acad. Sci. USA 88:7451-7455, August 1991. Generally, SP-B analogs should be designed to optimize their function in accord with the native SP-B protein based on topography, charge distribution, contribution and physical or chemical properties as described in Gordon, L. M., Horvath, S., Longo, M. L., Zasadzinski, J. A. N., Taeusch, H. W., Faull, K., Leung, C., and Waring, A. J., Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments, Protein Science, 5:1662-1675, 1996.
- With respect to the length of the molecule synthesized pursuant to the present invention, from the N-terminal end, the peptide analog of this invention is shorter than the native 79 residue peptide chain. The SP-B 1-25 homodimer is one example of a molecule that is shorter than the native protein, but that retains the critical function as described herein. Other N-terminal molecules may be created by truncation from the C-terminal end with preservation of the functional properties described above. Therefore, the invention contemplates molecules from between approximately 25 to 77 residues, preferably formed as a homodimer, and all integral values between 25 and 77. Specifically, with respect to α-helicity, other molecules having a length between 40 and 50 may yield a conformation preserving the function of the native SP-B protein.
- Therefore, other modifications in accord with the foregoing rationale may be made pursuant to this invention to create other SP-B N-terminal segment analogs or derivatives, particularly homodimers, to achieve both the benefits of the N-terminal fragment described herein and the physical and chemical properties of the native protein.
- Results of Administration of the SP-B 1-25 Dimer in an Animal Model of Acute Respiratory Distress Syndrome.
- To demonstrate the advantages of the preferred formulation of the present invention compared to an N-terminal monomer described in the literature (Gordon, L. M., Horvath, S., Longo, M., Zasadzinski, J A. M., Taeusch, H. W., Faull, K., Leung, C., and Waring, A. J., “Conformation and Molecular Topography of the N-terminal segment of Surfactant Protein B in Structure-Promoting Environments, Protein Science 5:1662-1675 (1996)), a commercially available pharmaceutical composition for respiratory disorders (Survanta®) and a phospholipid surfactant, comparative animal studies of lung function were conducted in mature lavaged rat lung and preterm rabbits.
- The experimental surfactant preparations were prepared by mixing synthetic peptides into a standard phospholipid mixture (PL) consisting of dipalmitoyl phosphatidylcholine (DPPC), 1-palmitoyl, 2-oloeyl phosphatidylglycerol (POPG), and palmitic acid (PA) (DPPC:POPG:PA=7:2:1 wt/wt/wt), creating: PL+3% monomeric SP-B1-25 (B1-25 monomer) and PL+3% dimeric SP-B1-25 (B1-25 dimer).
- The phospholipids and the synthetic peptide(s), stored in chloroform, were freeze-dried, added together, and the mixture was then rehydrated in 0.15 N NaCl over 48 h with gentle stirring at 37° C. The clinical surfactant Survanta®, containing phospholipids with SP-B and SP—C, was used as a standard. All surfactant preparations were prepared at a concentration of 25 mg of phospholipids/mL and administered in a dose of 100 mg of phospholipids/kg of body weight.
- Rats were anesthetized with 35 mg/kg of pentobarbital sodium and 80 mg/kg of ketamine by intraperitoneal injection. After placement of a tracheal cannula, the rats were supported on a rodent ventilator (Harvard Apparatus, South Natick, Mass.) with 100% oxygen, a tidal volume of 7.5 mL/kg and a rate of 60/min. An arterial line was placed in the abdominal aorta for serial measurements of arterial blood gases and the rats were paralyzed with 2 mg/kg of pancuronium bromide intravascularly. Only animals with PaO2 values >400 Torr while ventilated with 100% oxygen were included in the experiments. The lungs were gently lavaged 8-12 times with 8 mL of 0.9
% NaC 1 warmed to body temperature until the PaO2 in 100% oxygen had reached stable values of less than 100 Torr, at which time they Were treated with 100 mg/kg of surfactant (time=0 min). Arterial blood gases, tidal volume, peak inspiratory pressure (PIP), and positive end-expiratory pressure (PEEP) were determined at 15 minute intervals throughout the experiment. - After 2 hours of ventilation, the rats were sacrificed with the intramuscular administration of 100 mg/kg pentobarbital sodium and exsanguination and the lungs were degassed in situ. A pressure-volume curve was measured in situ in each pair of rat lungs to define lung mechanics. Lungs were inflated and deflated using a bidirectional Harvard pump coupled to a 50-mL glass syringe, and pressure was continuously recorded on a Gould multichannel recorder. Each pressure-volume curve was corrected for the compliance of the system by subtracting the pressure-volume curve of the pump-syringe unit carried out before each curve. Absence of air leaks was assessed by verifying that lung volumes changed less than 0.1 mL/min over 3 minutes at 30 cm H2O pressure. The lung volume measured at a pressure of 5 cm H2O (V5) was issued as an index of stability at low lung volumes, whereas lung volumes at a pressure of 30 cm H2O (V30) were assumed as total lung capacity. Each treatment group consisted of 8 animals. All experiments were performed humanely and with the approval of the Animal Care and Use Committee of the Harbor-UCLA Medical Center Research and Education Institute. The arterial/Alveolar PO2′ (a/A) ratio was calculated using the PaO2 PaCO2, and FiO2 values and used to express oxygenation. Oxygenation and data from the pressure-volume curves are given as mean±SEM with 8 rats in each experimental group.
- Groups of 8 rats were lavaged until surfactant-deficiency and were than treated with one of 4 surfactant preparations, i.e., PL, B1-25 dimer, B1-25 monomer, or Survanta®. Rats treated with B1-25 dimer surfactant reached the highest oxygenation values (arterial/Alveolar PO2 ratios) and rats treated with PL the lowest (FIG. 7). The surfactant preparations could be ranked as follows: B1-25 dimer>Survanta®>B1-25 monomer>PL surfactant.
- The group of rats treated with B1-25 dimer surfactant had the largest lung volumes on the postmortem pressure-volume curves, followed by those treated with Survanta®, B1-25 monomer, and PL surfactant (FIG. 8). All values are expressed as means±standard error (SEM).
- In a comparative study of lung function in preterm rabbits, the experimental surfactant preparations were prepared as described above for lavaged rats. Pregnant New Zealand White rabbits were preanesthetized at 27 day gestational age with 50 mg/kg ketamine and 5 mg/kg acepromazine by intramuscular injection and then given general anesthesia with 50 mg/kg ketamine intravenously prior to undergoing a cesarean section. Fetuses were sequentially delivered, weighed, and anesthetized with an intraperitoneal injection of a mixture of 10 mg/kg ketamine and 0.1 mg/kg acepromazine. The trachea of each newborn was exposed through a small incision in the anterior neck, and a short tube from an 18-gauge needle was tied in the trachea. Each rabbit was ventilated with 100% oxygen using an anesthesia bag and manometer for about five breaths and transferred to a temperature-controlled ventilator-plethysmograph system that permits the simultaneous ventilation of 10 newborn rabbits. The plethysmographs are a serial of 10 clear Plexiglas boxes, temperature-controlled at 37° C., that are connected to 10 rebreathing circuits containing soda lime and driven by a Sechrist infant ventilator (Sechrist Industries, Anaheim, Calif.). The rabbits were ventilated with 100% oxygen at a rate of 40 breaths/minute with a 1:1 inspiratory-to-expiratory time ratio. No positive end-expiratory pressure was used to avoid the air trapping that seems to occur in preterm rabbits. The initial peak inspiratory pressure was 30 cm H2O and peak pressure was adjusted individually to achieve a tidal volume of about 10 mL/kg as measured with a pneumotachometer (Validyne, Northridge, Calif.) and a multichannel recorder (Gould Inc., Cleveland, Ohio). Peak inspiratory pressure was limited at 35 cm H2O to avoid pneumothorax. Dynamic compliance was calculated by dividing tidal volume by peak inspiratory pressure and the body weight in kg (mL/kg/cm H2O) and monitored every 15 minutes.
- All preterm rabbits were treated with 100 mg/kg of an experimental surfactant after insertion of the endotracheal tube and prior to bagging. After 60 minutes of ventilation, each rabbit was sacrificed by an administration of an intrathecal injection of lidocaine and was disconnected from the ventilator. Pressure-volume curves were measured in situ to define lung mechanics. Lungs were inflated and deflated using a bidirectional Harvard pump coupled to a 10-mL glass syringe, and pressure was continuously recorded on a Gould multichannel recorder. Each pressure-volume curve was corrected for the compliance of the system by subtracting the pressure-volume curve of the pump/syringe unit carried out before each curve. Absence of air leaks was assessed by verifying that lung volumes changed less than 0.1 mL/minute over 3 minutes at 30 cm H2O pressure. Treatment groups consisted of 12 preterm rabbits. All experiments were performed humanely and with the approval of the Animal Care and Use Committee of the Harbor-UCLA Medical Center Research and Education Institute.
- Postmortem pressure-volume curves showed that lung volumes at 30 cm H2O pressure were highest for preterm rabbits treated with B1-25 dimer surfactant, followed by Survanta® and B1-25 monomer surfactant, and lowest for PL-surfactant (FIG. 9). All values are expressed as means±standard error (SEM).
- While the invention is susceptible to various modifications and alternative forms, specific examples thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the appended claims. All references cited herein are specifically incorporated by reference in their entirety.
-
1 4 1 79 PRT Homo sapiens 1 Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Cys Arg Ala Leu Ile Lys 1 5 10 15 Arg Ile Gln Ala Met Ile Pro Lys Gly Ala Leu Ala Val Ala Val Ala 20 25 30 Gln Val Cys Arg Val Val Pro Leu Val Ala Gly Gly Ile Cys Gln Cys 35 40 45 Leu Ala Glu Arg Tyr Ser Val Ile Leu Leu Asp Thr Leu Leu Gly Arg 50 55 60 Met Leu Pro Gln Leu Val Cys Arg Leu Val Leu Arg Cys Ser Met 65 70 75 2 25 PRT Homo sapiens misc_feature Native Human SP-B 1-25 2 Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Cys Arg Ala Leu Ile Lys 1 5 10 15 Arg Ile Gln Ala Met Ile Pro Lys Gly 20 25 3 25 PRT Homo sapiens misc_feature (11)..(11) SP-B 1-25 (Cys-11 > Ala-11) variant monomer 3 Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Ala Arg Ala Leu Ile Lys 1 5 10 15 Arg Ile Gln Ala Met Ile Pro Lys Gly 20 25 4 25 PRT Homo sapiens misc_feature (11)..(11) SP-B 1-25 (Cys-11 > Ala-11) variant 4 Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Ala Arg Ala Leu Ile Lys 1 5 10 15 Arg Ile Gln Ala Met Ile Pro Lys Gly 20 25
Claims (19)
1. A peptide analog of lung surfactant protein B comprising:
a dimer of a synthetic peptide from an N-terminal domain of mammalian lung surfactant protein B.
2. A peptide analog of claim 1 wherein the analog is a dimer of the N-terminal domain of amino acid residues 1-25.
3. The peptide analog of claim 1 wherein an amino acid residue 11 is alanine.
4. The peptide analog of claim 1 having a Cys 8 to Cys 8 disulfide link.
5. The peptide analog of claim 1 wherein the mammal is a human.
6. A method to treat respiratory distress syndrome comprising:
administering a pharmaceutically compatible composition comprised of a dimer of a synthetic peptide from an N-terminal domain of lung surfactant protein B.
7. The method of claim 6 wherein the pharmaceutically compatible composition is further comprised of administering an animal-derived lung surfactant protein.
8. The method of claim 7 wherein the animal-derived lung surfactant protein is a porcine lung lavage extract.
9. The method of claim 7 wherein the animal-derived lung surfactant protein is a calf lung lavage surfactant.
10. The method of claim 7 wherein the animal-derived lung surfactant protein is a bovine lung extract.
11. The method of claims 6, 7, 8, 9 or 10 wherein the pharmaceutical compatible composition is further comprised of a phospholipid.
12. The method of claim 11 wherein the phospholipid is dipalmitoylphosphatidylcholine.
13. A pharmaceutical composition comprising:
a peptide analog comprised of a dimer of synthetic peptide from an N-terminal domain of lung surfactant protein-B; and
an animal-derived lung surfactant.
14. The pharmaceutical composition of claim 13 wherein the peptide analog is human SP-B1-25.
15. The pharmaceutical composition of claim 13 wherein the peptide analog is a Cys 11 to Ala 11 variant of SP-B1-25.
16. The pharmaceutical composition of claims 13, 14 or 15 further comprising a phospholipid.
17. A peptide analog of mammalian lung surfactant protein B comprising:
a dimer of lung surfactant protein B having a Cys 8 to Cys 8 disulfide link.
18. The peptide analog of claim 17 wherein the dimer is a homodimer.
19. The peptide analog of claim 1 wherein the dimer is a homodimer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/730,964 US20040132967A1 (en) | 2000-02-29 | 2003-12-08 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/515,356 US6660833B1 (en) | 2000-02-29 | 2000-02-29 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
US10/730,964 US20040132967A1 (en) | 2000-02-29 | 2003-12-08 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,356 Division US6660833B1 (en) | 2000-02-29 | 2000-02-29 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040132967A1 true US20040132967A1 (en) | 2004-07-08 |
Family
ID=29712390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,356 Expired - Lifetime US6660833B1 (en) | 2000-02-29 | 2000-02-29 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
US10/730,964 Abandoned US20040132967A1 (en) | 2000-02-29 | 2003-12-08 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,356 Expired - Lifetime US6660833B1 (en) | 2000-02-29 | 2000-02-29 | Respiratory distress syndrome therapy with peptide analogs of human SP-B |
Country Status (1)
Country | Link |
---|---|
US (2) | US6660833B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100055164A1 (en) * | 2006-07-20 | 2010-03-04 | University Of Rochester | Synthetic lung surfactant and use thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0203590D0 (en) * | 2002-12-04 | 2002-12-04 | Siemens Elema Ab | Medical device |
SE0203591D0 (en) * | 2002-12-04 | 2002-12-04 | Siemens Elema Ab | Method of preparing a media clamp and a medical device |
US20060292600A1 (en) * | 2004-03-10 | 2006-12-28 | Corixa Corporation | Methods, compositions and kits for the detection and monitoring of lung cancer |
US7538090B1 (en) | 2004-05-21 | 2009-05-26 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Exogenous surfactant protein B mimic |
US7582312B2 (en) | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
EP2298349A1 (en) | 2005-01-06 | 2011-03-23 | Discovery Laboratories, Inc. | Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia |
CA2606688A1 (en) * | 2005-05-03 | 2006-11-09 | Ross Allen Ridsdale | Phospholipid formulations and uses thereof in lung disease detection and treatment |
WO2007100560A2 (en) * | 2006-02-28 | 2007-09-07 | Bristol-Myers Squibb Company | Use of dha and ara in the preparation of a composition for inducing the expression of pulmonary surfactant protein-b |
CA2663795A1 (en) * | 2006-09-19 | 2008-03-27 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations and methods for promoting mucus clearance |
US20100284969A1 (en) * | 2007-06-05 | 2010-11-11 | Frank Guarnieri | Methods and Compositions for Delivery of Medicaments to the Lungs |
US9289388B2 (en) | 2008-12-10 | 2016-03-22 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
WO2012077127A1 (en) | 2010-12-10 | 2012-06-14 | Indian Institute Of Technology, Bombay | A protein free surfactant composition for pulmonary diseases and a process for preparing the same |
WO2013188016A2 (en) | 2012-05-04 | 2013-12-19 | Discovery Laboratories, Inc. | Surfactant therapy for exposure to ionizing radiation |
WO2014207585A1 (en) * | 2013-06-24 | 2014-12-31 | Azargen Biotechnologies (Pty) Ltd | Production of human pulmonary surfactant protein b in plants |
US20230257446A1 (en) | 2020-01-28 | 2023-08-17 | Chiesi Farmaceutici S.P.A. | Polypeptides having improved properties |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547937A (en) * | 1992-04-10 | 1996-08-20 | Abbott Laboratories | Pulmonary surfactant protein fragments |
US5861481A (en) * | 1992-07-29 | 1999-01-19 | Merrell Pharmaceuticals Inc. | Peptide lung surfactants and therapeutic combinations |
US5874406A (en) * | 1994-05-31 | 1999-02-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synthetic peptide analogs of lung surface protein SP-C |
US5876970A (en) * | 1989-07-11 | 1999-03-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Surfactant compositions and methods |
-
2000
- 2000-02-29 US US09/515,356 patent/US6660833B1/en not_active Expired - Lifetime
-
2003
- 2003-12-08 US US10/730,964 patent/US20040132967A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876970A (en) * | 1989-07-11 | 1999-03-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Surfactant compositions and methods |
US5547937A (en) * | 1992-04-10 | 1996-08-20 | Abbott Laboratories | Pulmonary surfactant protein fragments |
US5861481A (en) * | 1992-07-29 | 1999-01-19 | Merrell Pharmaceuticals Inc. | Peptide lung surfactants and therapeutic combinations |
US5874406A (en) * | 1994-05-31 | 1999-02-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synthetic peptide analogs of lung surface protein SP-C |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100055164A1 (en) * | 2006-07-20 | 2010-03-04 | University Of Rochester | Synthetic lung surfactant and use thereof |
US8563683B2 (en) | 2006-07-20 | 2013-10-22 | University Of Rochester | Synthetic lung surfactant and use thereof |
US9447127B2 (en) | 2006-07-20 | 2016-09-20 | University Of Rochester | Synthetic lung surfactant and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US6660833B1 (en) | 2003-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6660833B1 (en) | Respiratory distress syndrome therapy with peptide analogs of human SP-B | |
AU2008256449B2 (en) | Reconstituted surfactants having improved properties | |
EP1833503B1 (en) | Pulmonary surfactant formulations | |
JP4754073B2 (en) | Artificial peptides with surface activity and their use in the production of artificial surfactants | |
US5164369A (en) | Pulmonary surfactant protein and related polypeptide | |
US5407914A (en) | Pulmonary surfactant protein and related polypeptides | |
SK282441B6 (en) | Polypeptide with activity of lung surfactant and pharmaceutical preparation containing it | |
US20230107377A1 (en) | Synthetic lung surfactant with enhanced stability and effectiveness | |
WO1995015980A1 (en) | Novel synthetic peptide, lung surfactant containing the same, and remedy for respiratory distress syndrome | |
Curstedt et al. | New synthetic surfactants–basic science | |
EP1131055B1 (en) | Treatment set containing lungsurfactant compositions | |
US20030091509A1 (en) | Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases | |
Mbagwu et al. | Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits | |
US20230257446A1 (en) | Polypeptides having improved properties | |
AU2002338882B2 (en) | Novel use of pulmonary surfactant | |
US20240158471A1 (en) | Synthetic lung surfactant with enhanced stability and effectiveness | |
Halliday | Airway proteins—surfactants | |
WO2015061412A1 (en) | Methods and compositions for promoting bronchioli dilatation | |
AU629233C (en) | Pulmonary surfactant protein and related polypeptide | |
PT99632B (en) | METHOD FOR PREPARING A THROMBIN LIGATION SUBSTANCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |